JAZZ Stock Recent News

While the top- and bottom-line numbers for Jazz (JAZZ) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $4.51 per share, beating the Zacks Consensus Estimate of $4.46 per share. This compares to earnings of $4.30 per share a year ago.

The biotech industry proved itself resilient in the face of the COVID-19 pandemic. With research from Mckinsey, venture capitalist ( VC ) companies increased investments from 2,200 in 2016 to 3,100 in 2021 in biotechnology (biotech) startups.

Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Jazz Pharmaceuticals' current valuation is significantly lower than the sector average, despite strong margins and a positive growth outlook, presenting a potential investment opportunity. The company is making progress in its clinical trials and is diversifying its product offerings to mitigate the impact of generic drugs entering the market. Despite some challenges, such as a lengthy regulatory approval process for a new product, Jazz Pharmaceuticals is well-positioned to achieve its target of $5 billion in revenues by 2025.

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

DUBLIN , May 30, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2023 Goldman Sachs Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, June 13, 2023, at 3:20 p.m.

Zanidatamab data to be featured in oral presentation at ASCO 2023 Webcast to follow on June 2, 2023 at 6:45 p.m. CT DUBLIN , May 25, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a webcast to review the zanidatamab biliary tract cancers (BTC) data being featured in an oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2023.

Jazz (JAZZ) reports dismal first-quarter results as earnings and sales miss expectations. The company reaffirms its financial guidance for 2023.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Andrea Flynn - VP & Head, IR Bruce Cozadd - Co-Founder, Chairman & CEO Daniel Swisher - President & COO Robert Iannone - EVP & Global Head, Research & Development Renee Gala - EVP & CFO Kim Sablich - EVP & GM, US Conference Call Participants Marc Goodman - SVB Securities Jason Gerberry - Bank of America Merrill Lynch Joseph Thome - TD Cowen Jeff Hung - Morgan Stanley Gregory Fraser - Truist Securities Balaji Prasad - Barclays Bank Ashwani Verma - UBS Brandon Folkes - Cantor Fitzgerald & Co. Ami Fadia - Needham & Company David Amsellem - Piper Sandler & Co. Gregory Renza - RBC Capital Markets Madhu Kumar - Goldman Sachs Group Operator Good day, and thank you for standing by. Welcome to the Q1 2023 Jazz Pharmaceuticals Earnings Conference Call.